Back to resources

Medicine Supply Notification: Disopyramide (Rythmodan) Retard 250mg Modified-Release Tablets and Disopyramide (Rythmodan) 100mg Capsules

2 July, 2024

The Centre for Pharmacy Postgraduate Education (CPPE) has issued a supply notification for Disopyramide (Rythmodan) Retard 250mg modified-release tablets and Disopyramide (Rythmodan) 100mg capsules. This article provides an overview of the current supply issues and offers guidance for healthcare professionals on managing this shortage.

Introduction

Disopyramide, marketed as Rythmodan, is an antiarrhythmic medication used to manage and treat certain types of irregular heartbeats. Due to recent supply issues, healthcare providers need to be aware of the alternatives and management strategies available during this period.

Current Supply Issues

  • Affected Medications: Disopyramide (Rythmodan) Retard 250mg modified-release tablets and Disopyramide (Rythmodan) 100mg capsules.
  • Impact: The shortage may affect the availability of these medications for patients who rely on them for controlling heart arrhythmias.

Guidance for Healthcare Professionals

  1. Assess Patient Needs: Evaluate the current medication requirements of patients using Disopyramide (Rythmodan) to determine the impact of the shortage.
  2. Alternative Medications: Consider prescribing alternative antiarrhythmic medications or formulations. Consultation with a cardiologist or specialist may be necessary to identify suitable alternatives.
  3. Patient Communication: Inform patients about the supply issue and discuss potential alternatives and any changes to their treatment plan.
  4. Monitoring and Support: Ensure continuous monitoring and support for patients transitioning to alternative treatments to manage their arrhythmias effectively.

Conclusion

The supply shortage of Disopyramide (Rythmodan) 250mg modified-release tablets and 100mg capsules requires healthcare professionals to take proactive steps in managing patient care. By exploring alternative treatments and maintaining clear communication, the impact of this shortage on patient health can be mitigated.

 

Read more: Medicine Supply Notification: Disopyramide (Rythmodan Retard® ) 250mg modified-release tablets and disopyramide (Rythmodan® ) 100mg capsules. Updated – Community Pharmacy England (cpe.org.uk)

Read more articles: Ashtons Resources – Improving quality and compliance in medicines management

Recent Resources